New Glycotoxin Inhibitor from

Safina Ghaffar, Rizwana Sanaullah Waraich, Raha Orfali, Areej Al-Taweel, Hanan Y Aati, Sonia Kamran, Shagufta Perveen

Abstract read

In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Cellular signaling crosstalk between osteoporosis and diabetes: Common mechanisms and therapeutic targets (Review).Biomedical reports · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Safina GhaffarBiomedical Research Center, Department of Biomedical & Biological Sciences, Sohail University, Karachi 78400, Pakistan.

Rizwana Sanaullah WaraichBiomedical Research Center, Department of Biomedical & Biological Sciences, Sohail University, Karachi 78400, Pakistan.ORCID 0000-0002-5560-5053

Raha OrfaliDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia.

Areej Al-TaweelDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia.

Hanan Y AatiDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia.ORCID 0000-0003-1598-2273

Sonia KamranDepartment of Chemistry, School of Computer, Mathematical and Natural Sciences, Morgan State University, Baltimore, MD 21251, USA.

Shagufta PerveenDepartment of Bacteriology, University of Wisconsin-Madison, Madison, WI 53706, USA.ORCID 0000-0002-3318-9861

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study intended to investigate the role of new natural compounds derived from the

Indexed as

Diabetes Mellitus, ExperimentalGlycation End Products, AdvancedInsulin ResistanceMuscle, SkeletalReceptor for Advanced Glycation End ProductsAnimalsGlycosidesHumansMaleMiceGlycation End Products, AdvancedGlycosidesReceptor for Advanced Glycation End Productsadvanced glycation end productsantidiabetic compoundinflammationoxidative stressreceptor for advance glycation end products

Identifiers

PMID39125053

DOI10.3390/molecules29153649

PMCPMC11314016

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.